Live price temporarily unavailable.
Halozyme Therapeutics (HALO) is a Health Care company in the Russell 1000. Latest news and coverage below.
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $146.7M | $316.6M | $151.9M | $196.0M | $267.6M | $443.3M | $660.1M | $829.3M | $1.02B | $1.40B |
| Growth (year over year) | +8.6% | +115.8% | −52.0% | +29.1% | +36.5% | +65.7% | +48.9% | +25.6% | +22.4% | +37.6% |
| Gross profit | $113.5M | $285.5M | $141.7M | $150.4M | $224.2M | $361.9M | $520.8M | $636.9M | $855.9M | $1.17B |
| Gross margin | 77.4% | 90.2% | 93.3% | 76.8% | 83.8% | 81.6% | 78.9% | 76.8% | 84.3% | 83.6% |
| Operating income | −$83.2M | $81.0M | −$69.3M | −$67.6M | $144.3M | $275.9M | $267.5M | $337.6M | $551.5M | $469.0M |
| Operating margin | −56.7% | 25.6% | −45.7% | −34.5% | 53.9% | 62.2% | 40.5% | 40.7% | 54.3% | 33.6% |
| Net income | −$103.0M | $63.0M | −$80.3M | −$72.2M | $129.1M | $402.7M | $202.1M | $281.6M | $444.1M | $316.9M |
| Net margin | −70.2% | 19.9% | −52.9% | −36.9% | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| EPS (diluted) | −$0.81 | $0.45 | −$0.56 | −$0.50 | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| Balance sheet | ||||||||||
| Cash and equivalents | $66.8M | $168.7M | $57.9M | $120.2M | $147.7M | $118.7M | $234.2M | $118.4M | $115.8M | $133.8M |
| Total assets | $261.5M | $519.9M | $440.2M | $565.9M | $579.9M | $1.10B | $1.84B | $1.73B | $2.06B | $2.53B |
| Total liabilities | $294.0M | $311.6M | $191.4M | $474.1M | $428.9M | $907.5M | $1.67B | $1.65B | $1.70B | $2.48B |
| Long-term debt | $199.2M | $125.1M | $34.9M | $383.0M | $0 | $787.3M | $1.49B | $1.50B | $1.51B | $2.14B |
| Shareholders' equity | −$32.5M | $208.4M | $248.9M | $91.8M | $151.0M | $197.0M | $169.8M | $83.8M | $363.8M | $48.8M |
| Cash flow | ||||||||||
| Operating cash flow | −$50.4M | $134.1M | −$49.5M | −$85.4M | $55.5M | $299.4M | $240.1M | $388.6M | $479.1M | $651.6M |
| Capital expenditure | $3.14M | $1.35M | $4.66M | $4.04M | $2.50M | $1.46M | $4.81M | $15.3M | $10.7M | $6.97M |
| Free cash flow | −$53.5M | $132.7M | −$54.2M | −$89.5M | $53.0M | $298.0M | $235.3M | $373.3M | $468.4M | $644.6M |
| Share buybacks | — | $0 | $0 | $200.0M | $150.1M | $350.1M | $200.0M | $402.4M | $250.0M | $342.4M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $290.1M | $298.0M | $264.9M | $325.7M | $354.3M | $451.8M | $376.7M | $481.0M |
| Growth (year over year) | +34.3% | +29.5% | +35.2% | +40.8% | +22.1% | +51.6% | +42.2% | +47.7% |
| Gross profit | $240.7M | $256.0M | $216.5M | $279.4M | $299.0M | $373.0M | $297.5M | $401.8M |
| Gross margin | 83.0% | 85.9% | 81.7% | 85.8% | 84.4% | 82.6% | 79.0% | 83.5% |
| Operating income | $163.2M | $175.5M | $141.5M | $202.4M | $217.9M | −$92.9M | $184.5M | $287.7M |
| Operating margin | 56.3% | 58.9% | 53.4% | 62.2% | 61.5% | −20.6% | 49.0% | 59.8% |
| Net income | $137.0M | $137.0M | $118.1M | $165.2M | $175.2M | −$141.6M | $150.0M | $229.9M |
| Net margin | 47.2% | 46.0% | 44.6% | 50.7% | 49.5% | −31.3% | 39.8% | 47.8% |
| EPS (diluted) | $1.05 | $1.06 | $0.93 | $1.33 | $1.43 | −$1.13 | $1.22 | $1.90 |
| Balance sheet | ||||||||
| Cash and equivalents | $154.3M | $115.8M | $176.3M | $61.9M | $419.7M | $133.8M | $309.7M | $163.1M |
| Total assets | $2.12B | $2.06B | $2.20B | $2.05B | $2.22B | $2.53B | $2.67B | $2.58B |
| Total liabilities | $1.67B | $1.70B | $1.71B | $1.72B | $1.72B | $2.48B | $2.45B | $2.43B |
| Long-term debt | $1.50B | $1.51B | $1.51B | $1.51B | $800.1M | $2.14B | $1.94B | $1.94B |
| Shareholders' equity | $452.7M | $363.8M | $482.3M | $332.7M | $503.9M | $48.8M | $219.6M | $143.5M |
| Cash flow | ||||||||
| Operating cash flow | $115.4M | $178.5M | $154.2M | $99.7M | $178.6M | $219.0M | $180.1M | $240.9M |
| Capital expenditure | $1.52M | $3.05M | $950.0K | $1.56M | $3.03M | $1.43M | $3.74M | $4.17M |
| Free cash flow | $113.9M | $175.4M | $153.3M | $98.1M | $175.6M | $217.6M | $176.3M | $236.7M |
| Share buybacks | $0 | $250.0M | — | — | $38.9M | $0 | — | — |
From Halozyme Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Halozyme Therapeutics in our feed yet.